

REGULATION
OF THE MINISTER FOR HEALTH¹⁾

of [date] 2026

**amending the Regulation on the list of psychotropic substances, narcotic drugs and
new psychoactive substances^{2), 3)}**

Pursuant to Article 44f of the Act of 29 July 2005 on the combating of drug addiction (Journal of Laws of 2023, item 1939), the following is hereby decreed:

§ 1. The Regulation of the Minister for Health of 17 August 2018 on the list of psychotropic substances, narcotic drugs and new psychoactive substances (Journal of Laws of 2024, item 1139; and of 2025, item 598) is amended as follows:

1) in reference no. 2 to the title of the Regulation, in subparagraph 4, the full stop is replaced by a semicolon and the following subparagraph 5 is added:

‘5) Commission Delegated Directive (EU) 2025/2062 of 14 October 2025 amending the Annex to Council Framework Decision 2004/757/JHA as regards the inclusion of new psychoactive substances in the definition of drug (OJ L, 2025/2062, 23.12.2025).’;

2) In Annex 1 to this Regulation:

a) in Part ‘1. GROUP I-P PSYCHOTROPIC SUBSTANCES’

- item 96 of the table is replaced by the following:

96		Tetrahydrocannabinols, the following isomers and their	
----	--	--	--

¹⁾ The Minister for Health manages the government health department pursuant to § 1(2) of the Regulation of the Prime Minister of 25 July 2025 concerning the specific scope of activities of the Minister for Health (Journal of Laws [Dziennik Ustaw], item 1004).

²⁾ This Regulation was notified to the European Commission on ... under number ..., pursuant to § 4 of the Cabinet Regulation of 23 December 2002 on the functioning of the national system for notification of standards and legal acts (Journal of Laws, item 2039, and 2004, item 597), which implements the Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services (harmonisation) (OJ L 241 of 17.9.2015, p. 1).

³⁾ This Regulation implements Commission Delegated Directive (EU) 2025/2062 of 14 October 2025 amending the Annex to Council Framework Decision 2004/757/JHA as regards the inclusion of new psychoactive substances in the definition of drug (OJ L, 2025/2062, 23.12.2025).

		stereochemical variants: - $\Delta^{6a,10a}$-tetrahydrocannabinol, $\Delta^{6a,10a}$-THC, - $\Delta^{6a,7}$-tetrahydrocannabinol, $\Delta^{6a,7}$-THC, - Δ^7-tetrahydrocannabinol, Δ^7-THC, - Δ^8-tetrahydrocannabinol, Δ^8-THC, - Δ^{10}-tetrahydrocannabinol, Δ^{10}-THC, - $\Delta^{9,11}$-tetrahydrocannabinol, $\Delta^{9,11}$-THC, <i>exo</i>-THC	- 7,8,9,10-tetrahydro-6,6,9-trimethyl-3-pentyl-6<i>H</i>-dibenzo[<i>b,d</i>]pyran-1-ol, - (9<i>R</i>,10<i>aR</i>)-8,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6<i>H</i>-dibenzo[<i>b,d</i>]pyran-1-ol, - (6<i>aR</i>,9<i>R</i>,10<i>aR</i>)-6a,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6<i>H</i>-dibenzo[<i>b,d</i>]pyran-1-ol, - (6<i>aR</i>,10<i>aR</i>)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6<i>H</i>-dibenzo[<i>b,d</i>]pyran-1-ol, - 6a,7,8,9-tetrahydro-6,6,9-trimethyl-3-pentyl-6<i>H</i>-dibenzo[<i>b,d</i>]pyran-1-ol - (6<i>aR</i>,10<i>aR</i>)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-9-methylene-3-pentyl-6<i>H</i>-dibenzo[<i>b,d</i>]pyran-1-ol
--	--	---	--

- item 99 is repealed,

b) in Part ‘2. GROUP II-P PSYCHOTROPIC SUBSTANCES’, the following 83–85 items are added:

83	HHC	Hexahydrocannabinol	6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-6 <i>H</i> -dibenzo[<i>b,d</i>]pyran-1-ol
84	2-MMC	2-Methylmethcathinone	2-(methylamino)-1-(2-methylphenyl)propane-1-one
85	NEP	alfaethylaminopenthiophenone, N-ethylnorpentedrone, alfaethylaminovalerophenone, alpha-EFAPP	2-(ethylamino)-1-phenyl-1-pentanone

c) In Part ‘4. GROUP IV-P PSYCHOTROPIC SUBSTANCES’, the following item 81 is added to the table:

81	CARISOPRODOL		1-methylethylcarbamate (<i>RS</i>)-2-[(carbamoyloxy)methyl]-2-methylpentyl
----	--------------	--	--

3) in Annex 2 to the Regulation, in Part ‘1. GROUP I-N PSYCHOTROPIC SUBSTANCES’, the following 212–216 items are added:

212	PROTONITAZENE		<i>N,N</i> -diethyl-5-nitro-2-[(4-propoxyphenyl)methyl]-1 <i>H</i> -benzimidazole-1-ethanamine
213	PROTONITAZEPYNE	N-pyrrolidinopropanitazene	5-nitro-2-[4-propoxyphenyl)methyl]-1-(2-pyrrolidine-1-ylethyl)-1 <i>H</i> -benzimidazole
214	METONITAZEPYNE	N-pyrrolidino menitazene	2-[(4-methoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidine-1-ylethyl)-1 <i>H</i> -benzimidazole
215	ETONITAZEPYNE	N-piperidino etonitazene	2-[(4-ethoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidine-1-ylethyl)-1 <i>H</i> -benzimidazole
216	N-DESETHYL ISOTONITAZENE	Norizotonitazene	<i>N</i> -ethyl-2-[[4-(1-methylethoxy)phenyl)methyl]-5-nitro-1 <i>H</i> -benzimidazole-1-ethanamine

4) in Annex 3 to the Regulation:

a) in Part ‘1. List of new psychoactive substances with their names and chemical notations’,

- item 13 is repealed,
- the following items 67 and 68 are added:

67	Δ^8 -THCP	Δ^8 -tetrahydrocannabiforol, JWH-091	(6 <i>aR</i> ,10 <i>aR</i>)-6 <i>a</i> ,7,10,10 <i>a</i> -tetrahydro-6,6,9-trimethyl-3-heptyl-6 <i>H</i> -dibenzo[<i>b,d</i>]pyran-1-ol
68	Δ^9 -THCP-O	Δ^9 -tetrahydrocannabiforol acetate	(6 <i>aR</i> ,10 <i>aR</i>)-6 <i>a</i> ,7,8,10 <i>a</i> -tetrahydro-6,6,9-trimethyl-3-heptyl-6 <i>H</i> -dibenzo[<i>b,d</i>]pyran-1-ol acetate

b) in Part ‘2. 2-phenylethylamine derivatives – I-NPS group’, in subparagraph 2.2:

- in point (a), the words ‘It is also possible to create a cyclic system between the nitrogen atom and parts of element B (substitutes R3 to R6).’ are replaced by the words ‘It is also possible to create an aliphatic cyclic system between the nitrogen atom and parts of element B (substitutes R3 to R6).’,
- in point (b), the words ‘or the formation of a bond between substitutes R3 to R6, leading to ring closure and the formation of a cyclic structure’ are replaced by the words ‘or the formation of a bond between substitutes R3 to R6, leading to ring closure and the formation of an aliphatic cyclic structure’,

c) in Part ‘3. Derivatives of cathinone (2-amino-1-phenyl-1-propanone) – group II-NPS, in subparagraph 3.2:

- in point (a), the words ‘It is also possible to create a cyclic system between the nitrogen atom and part of element B (substitutes R3 to R4).’ are replaced by the words ‘It is also possible to create an aliphatic cyclic system between the nitrogen atom and part of element B (substitutes R3 to R4).’,
- in point (b), the words ‘or the formation of a bond between substitutes R3 to R4, leading to ring closure and the formation of a cyclic structure’ are replaced by the words ‘or the formation of a bond between substitutes R3 to R4, leading to ring closure and the formation of an aliphatic cyclic structure’.

§ 2. The Regulation shall enter into force 14 days after its publication.

THE MINISTER OF HEALTH